Tuberculosis (TB) is the number one infectious disease killer worldwide and is the leading cause of death for people living with HIV. Multidrug-resistant TB (MDR-TB) continues to pose a serious threat to health security, with the WHO estimating almost 480,000 cases of MDR-TB in 2019. Extensively drug-resistant TB (XDR-TB) poses health security risks.
There has been increasing recognition of the need for new drugs, diagnostics, vaccines, and tools to enhance infection control, surveillance, and access and adherence to TB treatment. Global focus, such as at the UN High-Level Meeting on Tuberculosis in 2018, has highlighted TB as an urgent health security priority.
GHPC has closely examined TB epidemiology; U.S. and international approaches to combating global TB; drug-resistant TB and broader issues of antimicrobial resistance; the need to develop a more effective TB vaccine; as well as health system strengthening efforts including affordable access and models of delivery of new drugs.